Jane Street’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $870K | Buy |
39,100
+22,800
| +140% | +$545K | ﹤0.01% | 6819 |
|
|
2025
Q4 | $435K | Sell |
16,300
-37,900
| -70% | -$906K | ﹤0.01% | 8014 |
|
|
2025
Q3 | $1.16M | Buy |
54,200
+42,200
| +352% | +$998K | ﹤0.01% | 5991 |
|
|
2025
Q2 | $259K | Sell |
12,000
-1,200
| -9% | -$22.3K | ﹤0.01% | 8112 |
|
|
2025
Q1 | $219K | Buy |
+13,200
| New | +$240K | ﹤0.01% | 8316 |
|
|
2024
Q4 | – | Sell |
-16,700
| Closed | -$257K | – | 9269 |
|
|
2024
Q3 | $257K | Sell |
16,700
-1,800
| -10% | -$30K | ﹤0.01% | 8281 |
|
|
2024
Q2 | $301K | Sell |
18,500
-911,200
| -98% | -$14.7M | ﹤0.01% | 7800 |
|
|
2024
Q1 | $17.2M | Buy |
929,700
+849,700
| +1,062% | +$21.1M | ﹤0.01% | 1309 |
|
|
2023
Q4 | $2.5M | Sell |
80,000
-503,200
| -86% | -$12M | ﹤0.01% | 3936 |
|
|
2023
Q3 | $12.2M | Buy |
583,200
+573,100
| +5,674% | +$15.6M | ﹤0.01% | 1569 |
|
|
2023
Q2 | $242K | Sell |
10,100
-500
| -5% | -$11.1K | ﹤0.01% | 7437 |
|
|
2023
Q1 | $199K | Sell |
10,600
-400
| -4% | -$7.62K | ﹤0.01% | 7842 |
|
|
2022
Q4 | $175K | Sell |
11,000
-83,000
| -88% | -$1.3M | ﹤0.01% | 7764 |
|
|
2022
Q3 | $1.54M | Sell |
94,000
-107,000
| -53% | -$1.73M | ﹤0.01% | 4636 |
|
|
2022
Q2 | $2.83M | Buy |
201,000
+103,900
| +107% | +$1.94M | ﹤0.01% | 3553 |
|
|
2022
Q1 | $2.35M | Sell |
97,100
-66,500
| -41% | -$1.61M | ﹤0.01% | 4435 |
|
|
2021
Q4 | $3.82M | Buy |
163,600
+99,000
| +153% | +$1.99M | ﹤0.01% | 3279 |
|
|
2021
Q3 | $1.07M | Sell |
64,600
-19,800
| -23% | -$382K | ﹤0.01% | 5772 |
|
|
2021
Q2 | $2.06M | Sell |
84,400
-459,400
| -84% | -$10.4M | ﹤0.01% | 4281 |
|
|
2021
Q1 | $14M | Buy |
543,800
+467,700
| +615% | +$20.6M | 0.01% | 1255 |
|
|
2020
Q4 | $4.07M | Sell |
76,100
-28,900
| -28% | -$1.43M | ﹤0.01% | 2389 |
|
|
2020
Q3 | $4.33M | Buy |
105,000
+87,400
| +497% | +$3.77M | ﹤0.01% | 2013 |
|
|
2020
Q2 | $853K | Buy |
17,600
+9,400
| +115% | +$451K | ﹤0.01% | 4292 |
|
|
2020
Q1 | $346K | Buy |
+8,200
| New | +$338K | ﹤0.01% | 4049 |
|
|
2019
Q4 | – | Sell |
-22,500
| Closed | -$810K | – | 4982 |
|
|
2019
Q3 | $810K | Buy |
+22,500
| New | +$682K | ﹤0.01% | 2901 |
|
|
2018
Q2 | – | Sell |
-9,600
| Closed | -$216K | – | 4892 |
|
|
2018
Q1 | $216K | Hold |
9,600
| – | – | ﹤0.01% | 4383 |
|
|
2017
Q4 | $289K | Buy |
+9,600
| New | +$307K | ﹤0.01% | 3803 |
|
|
2017
Q1 | – | Sell |
-112,800
| Closed | -$3.25M | – | 4055 |
|
|
2016
Q4 | $3.25M | Buy |
+112,800
| New | +$2.98M | 0.01% | 947 |
|
|
2016
Q2 | – | Sell |
-47,900
| Closed | -$1.34M | – | 3996 |
|
|
2016
Q1 | $1.34M | Buy |
+47,900
| New | +$1.04M | 0.01% | 1569 |
|
Other funds holding ACAD
BBA
VPM
RI
VCM
PAI
Jane Street's ACAD Position: Q1 2026 in Review
Jane Street opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 803,265 shares worth $17.9M. The stake represents ﹤0.01% of the portfolio and ranks #1883 among its holdings. This is a return to the name: Jane Street previously reported a position in ACAD as recently as Q3 2025.
Jane Street first reported a position in ACAD in Q3 2013 and has held it in 40 quarters since. 341 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.
- Jane Street held 803,265 shares of Acadia Pharmaceuticals worth $17.9M as of Q1 2026.
- Acadia Pharmaceuticals was a new Jane Street position in Q1 2026.
- Acadia Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #1883 holding.
- Jane Street first reported a position in Acadia Pharmaceuticals in Q3 2013 and has held it in 40 quarters since.
- 341 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.